Celltrion Presents New Post-hoc Analysis Results on Remsima SC at ECCO

"Remsima SC Demonstrates Treatment Effectiveness in IBD Patients with Therapy Interruptions"

Celltrion announced on the 19th that it will participate in the 2026 European Crohn's and Colitis Organisation (ECCO) Congress, held in Stockholm, Sweden from February 18 to 21 (local time), where it will seek to demonstrate its accumulated clinical experience and portfolio competitiveness in the field of autoimmune diseases.

Now in its 21st year, ECCO is a leading global academic congress in the field of inflammatory bowel disease (IBD). Experts from around the world gather to share the latest research, clinical information, and trends in therapeutic development. Celltrion will operate an independent promotional booth and conduct various academic activities, including a symposium and poster presentations.

On the first day of the congress, Celltrion will unveil for the first time new post-hoc analysis results from a phase 3 clinical study of Remsima SC (infliximab) in patients with Crohn's disease or ulcerative colitis. According to the data, when infliximab 240 mg subcutaneous (SC) injection was administered to a patient group that had received placebo for at least 16 weeks after discontinuing infliximab intravenous (IV) treatment, most patients showed a rapid recovery of clinical response. Efficacy and safety were stably maintained up to week 102, the end of the follow-up period. IBD patients frequently experience treatment interruptions for both clinical and non-clinical reasons. These data are being evaluated as showing that infliximab SC administration can be a meaningful treatment strategy even after treatment discontinuation.

At the symposium, under the theme "Improving Patient Care with Infliximab SC Formulation: Clinical Review and Discussion," participants will discuss treatment optimization strategies based on real-world clinical data. In addition, expert sessions at the booth will cover topics such as the clinical significance of ultra-long-term treatment outcomes after switching from IV to SC; the need for combination therapy with TNF inhibitors in IBD treatment; and implications of switching to infliximab SC based on real-world Nordic clinical data.

Through this congress, Celltrion plans to highlight the competitiveness of its IBD portfolio, including its infliximab therapies. Celltrion is the only company that has launched all three formulations of infliximab on the market: IV lyophilized, high-concentration IV liquid, and SC formulation. In particular, the recently approved high-concentration IV liquid formulation is expected to contribute to expanding Remsima prescriptions in the market, as it improves convenience and efficiency in clinical settings by minimizing preparation time and staffing requirements.

In addition, the company plans to drive tangible sales growth by frontlining a total of four IBD treatments—Remsima, Remsima SC, Yuflyma, and Steqima—to provide autoimmune disease treatment options tailored to clinical practice and thereby increase prescribing preference among healthcare professionals.

A Celltrion representative said, "Every year at ECCO, we consistently present evidence-based data supporting prescriptions of our therapies, and we can clearly feel the growing interest from healthcare professionals on site," adding, "We will continue to conduct data-driven research that reflects the needs of medical practice and develop innovative formulations, thereby enhancing the competitiveness of our autoimmune disease treatments and further strengthening our position in the market."

Meanwhile, Celltrion posted a record-high annual revenue of 4.1625 trillion won last year, with Remsima and Remsima SC accounting for about 45% of total revenue at 1.8889 trillion won, solidifying their status as core product lines.

This content was produced with the assistance of AI translation services.